tbuckley/cabot-search huggingface dataset:
KB004, a Novel Non-Fucosylated Humaneered® Antibody, Targeting EphA3, Is Active and Well Tolerated in a Phase I/II Study of Advanced Hematologic Malignancies
Authors: Ronan T Swords, Andrew H Wei, Simon Durrant, Anjali S. Advani, Mark S Hertzberg, Ian D Lewis, Peter L. Greenberg, Jorge E. Cortes, Geoff T Yarranton, Jackie M. Walling, Jeffrey E. Lancet
Journal: Blood (2014)
Challenging Dogmas - Or How Much Evidence Is Necessary To Claim That There Is a Direct Developmental and Functional Link Between The Primordial Germ Cell (PGC) Lineage and Hematopoiesis?
Authors: Magdalena Kucia, Magda Maj, Kasia Mierzejewska, Dong-Myung Shin, Janina Ratajczak, Mariusz Z Ratajczak
Journal: Blood (2013)
Predictors of clinical outcome in patients with bone metastases from prostate cancer
Authors: F. Saad, R. E. Coleman, R. Cook, M. R. Smith, J. E. Brown, J. Y. Hei, Y. M. Chen
Journal: Journal of Clinical Oncology (2006)

4555 Background: Bone metastases are a significant cause of morbidity in patients with prostate cancer (PC). To assess the predictive value of bone markers and fractures for clinical outcome in patients with bone metastases from PC, we conducted a retrospective analysis of patients in a large, randomized, controlled trial of zoledronic acid. Methods: Data were analyzed in patients treated with 4 mg zoledronic acid or placebo who had bone marker (n = 411) or fracture (n = 640) information. Cox regression models, adjusted for treatment group, were used to assess the association between bone markers (urinary N-telopeptide [NTX] and bone alkaline phosphatase [BALP]) or fractures (time-dependent variable) and the risk of death or of experiencing a first skeletal-related event (SRE) on study. For bone marker analyses, patients were grouped by low (&lt; 50 nmol/mmol creatinine), moderate (50 to 99), or high (≥ 100) NTX levels and by low (&lt; 146 U/L) or high (≥ 146) BALP. Results: Patients who experienced a fracture on study (19%) had shorter survival compared with patients who did not; the hazard ratio for death was 1.29 (95% CI = 1.01, 1.65; P = .04), suggesting 29% increased risk of death among these patients. When adjusted for previous SRE and baseline ECOG performance status ≥ 2, the risk for death associated with fractures was increased by 23% and trended toward statistical significance (P = .10). Patients with high NTX levels had significantly increased risk of SREs and disease progression (P &lt; .001) compared with patients with low NTX. Relative to low NTX levels, high and moderate NTX levels were associated with a 5.72-fold (95% CI = 4.04, 8.11; P &lt; .001) and 4.10-fold (95% CI = 2.81, 5.97; P &lt; .001) increased risk of death, respectively. High BALP also significantly correlated with an increased risk of a first on-study SRE (P = .028) and bone lesion progression (P &lt; .001). Conclusions: These analyses suggest that pathologic fractures are associated with increased risk if death and that high bone marker levels are associated with increased risk of SREs, bone lesion progression, and shorter survival in patients with PC and bone metastases. The results support appropriate treatment for the prevention of fractures and to decrease bone marker levels. [Table: see text]
Impact of Cytogenetics on Outcome of AML after Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Tatiana L Gindina, Nikolay N Mamaev, Boris V Afanasyev, Sergey N Bondarenko, Alexander Alyanskiy, Olga Slesarchuk, Ivan S Moiseev, Svetlana V Razumova, Lyudmila Zubarovskaya
Journal: Blood (2015)
Barry William Serpell
Authors: M G Serpell
Journal: BMJ (2016)

Barry William Serpell was born in Burnley, Lancashire, UK, the son of William and Margaret (Sweeney) Serpell. He studied medicine at Edinburgh University, Scotland, from 1954 to 1959. On completing his preregistration year in Douglas on the Isle of Man, Barry entered the British army, fulfilling his duty to the national service. He served three years in Malaya, now Malaysia, and two …
Cataract Surgery in Children from Birth to Less than 13 Years of Age
Authors: Michael X. Repka, Trevano W. Dean, Elizabeth L. Lazar, Kimberly G. Yen, Phoebe D. Lenhart, Sharon F. Freedman, Denise Hug, Bahram Rahmani, Serena X. Wang, Raymond T. Kraker, David K. Wallace
Journal: Ophthalmology (2016)
The Bcr-Abl Kinase Inhibitor INNO-406 Induces Autophagy and Different Modes of Cell Death Execution in Bcr-Abl-Positive Leukemias.
Authors: Yuri Kamitsuji, Junya Kuroda, Shinya Kimura, Ken-ichiro Watanabe, Eishi Ashihara, Yoshihiro Yui, Motonobu Watanabe, Hiroshi Matsubara, Yasuhiro Mizushima, Yoshimi Hiraumi, Hideo Tanaka, Eri Kawata, Taira Maekawa, Tatsutoshi Nakahata, Souichi Adachi
Journal: Blood (2007)
Human T Cells with Distinct Specificities Mediate Graft-Versus-Leukemia Reactivity and Xenogeneic Graft-Versus-Host Disease in a NOD/Scid Mouse Model for Human Acute Leukemia.
Authors: Sanja Stevanovic, Bart Nijmeijer, Marianke Lj Van Schie, Roelof Willemze, Marieke Griffioen, J.H. Frederik Falkenburg
Journal: Blood (2009)
Abstract 2108: Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities
Authors: Luis A. Martinez, Madhusudhan Kollareddy
Journal: Cancer Research (2015)

Abstract Mutant p53 (mtp53) is an oncogene that drives cancer cell proliferation. We found that mtp53 associates with the promoters of numerous nucleotide metabolism genes (NMG). Mtp53 knockdown reduced NMG expression and substantially depleted nucleotide pools. Decreased GTP levels correlated with reduced activation of GTP dependent proteins (GTPases) and reduced invasiveness. Addition of exogenous GTP restored the invasiveness of mtp53 knockdown cells, suggesting that mtp53 promotes invasion by increasing GTP. Additionally, mtp53 creates a dependency on the nucleotide salvage pathway enzyme deoxycytidine kinase (dCK) for the maintenance of a proper balance in dNTP pools required for proliferation. These data indicate that mtp53 harboring cells have acquired a synthetic sick or lethal phenotype relationship with the nucleotide salvage pathway. Finally, elevated expression of NMG correlates with mutant p53 status and poor prognosis in breast cancer patients. Thus, mtp53's control of nucleotide biosynthesis has both a driving and sustaining role in cancer development. Citation Format: Luis A. Martinez, Madhusudhan Kollareddy. Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2108. doi:10.1158/1538-7445.AM2015-2108
GW26-e5347 Recovery of Mesenchymal Stem Cells Homing to Rabbit Myocardial Ischemic Infarct Area by Cu-microbubble Treatment
Authors: Lili Meng, Wen Sun, Xiaorong Sun, Lin Bai, Hongge Wang, Ning Wang, Y. James Kang
Journal: Journal of the American College of Cardiology (2015)
What drives neutrophils to the alveoli in ARDS?
Authors: Rachel L Zemans, Michael A Matthay
Journal: Thorax (2016)

Neutrophil influx into the extravascular compartments of the lungs is a defining characteristic of the Acute Respiratory Distress Syndrome (ARDS).1 During ARDS, circulating neutrophils become primed, resulting in reduced deformability and retention within the pulmonary capillary bed2 ,3 followed by migration across the endothelium, through the interstitium and across the epithelium into the airspaces.4 As neutrophils migrate, they may become activated to phagocytose invading pathogens and release oxidants, proteases and neutrophil extracellular traps, all of which play a role in killing pathogens. Although neutrophils may migrate into the airspaces without inducing an increase in protein permeability under certain conditions,5 in ARDS neutrophils and their toxic mediators can cause tissue injury, including an increase in lung epithelial and endothelial permeability6–9 which leads to the influx of protein-rich alveolar oedema and arterial hypoxaemia.10 In fact, mortality from ARDS correlates with the extent of neutrophilia in the lung.1 Treatment for ARDS is mainly supportive, consisting of low tidal volume ventilation and fluid restriction, approaches which have substantially improved outcomes. However, to further improve outcomes, specific therapies to limit inflammatory lung injury while preserving host defense are needed. Therefore, it is critical that we understand the mechanisms regulating neutrophil recruitment, priming, activation and effector functions.

Leucocyte chemokines are classified into several families based on the position of cysteine (C) residues: CXC, CC, C and CX3C.11 Neutrophil migration has classically been thought to be driven by the CXC chemokines, with CXCL8 (interleukin 8) in humans and its orthologs CXCL1 (KC) and CXCL2 (MIP2) in mice being the prototypical neutrophil chemokines.12 CXC chemokines are elevated in patients with ARDS13 and animal models of lung injury,7 ,12 and CXCL8 levels are predictive of disease development,14 severity15 and mortality.16 However, although CXC …
Single-Cell Genetic Analysis Reveals The Genetic Composition Of Founder Clones, Phylogenetic Patterns Of Branching and Parallel Evolution, and Clonal Fluctuations Following Patient Treatment In Multiple Myeloma
Authors: Lorenzo Melchor, Annamaria Brioli, Christopher P Wardell, Alexander Murison, Nicola E Potter, Martin F Kaiser, Rosemary A Fryer, David C Johnson, Dil Begum, Sanna Hulkki, Gowri Vijayaraghavan, Ian Titley, Michele Cavo, Faith E Davies, Brian A Walker, Gareth J Morgan
Journal: Blood (2013)
The impact of tumor cavitations on objective and metabolic response assessment in a phase II study of erlotinib and sorafenib in patients with advanced non-small cell lung cancer (NSCLC)
Authors: Joline S. Lind, Egbert F. Smit, Hendricus Groen, Anne-Marie C. Dingemans, Otto S. Hoekstra, Virginie Frings
Journal: Journal of Thoracic Oncology (2009)
Elevated Circulating Platelet-Derived Microparticles in Ph1 Negative Chronic Myeloproliferative Disorders.
Authors: Véronique Tintillier-Colin, Nathalie Cambier, Emmanuelle Bourgeois-Petit, Christian Rose, Gérard Forzy, Jean-Loup Demory, Agnès Charpentier
Journal: Blood (2009)
Patients have rising expectations
Authors: A G Chappell
Journal: BMJ (1995)

EDITOR,—Richard Hobbs's editorial on the increase in emergency admissions—one of the most difficult and important problems facing doctors in district general hospitals—is disappointing in its bland analysis.1 The problem is certainly the rising tide of acute medical admissions, which reached a peak in 1993-4 but has been going on for a long time.2 A good deal is known about these admissions (Welsh Health Planning Forum expert workshop, 1994).

In my hospital, which serves a population of 140000 and has an integrated service …
The New Targeted Nanoparticles: Tf-Peg-PLL-PLGA Combined with Daunorubicin Overcome Hypoxia Induced Drug Resistance of K562 Cells
Authors: Ping Liu, Liting Guo, Fei Wang, Guohua Xia, Yonglu Wang, Xueming Li, Huihui Song, Wei Chen, Haixiang Yin, Baoan Chen
Journal: Blood (2014)
GW26-e2465 Low frequency electromagnetic fields in noninvasive left stellate ganglia stimulation prevents ventricular arrhythmia in myocardial infarction canine model
Authors: Songyun Wang, Xiaoya Zhou, Zhuo Wang, Bing Huang, Liping Zhou, Mingxian Chen, Lilei Yu, Hong Jiang
Journal: Journal of the American College of Cardiology (2015)
Prevalence and Characteristics of Survivors from Adult Acute Myeloid Leukemia (AML) in Sweden 2014
Authors: Gunnar Juliusson, Vladimir Lazarevic, Petar Antunovic, Asa Rangert Derolf, Hege Garelius, Sören Lehmann, Kristina Myhr-Eriksson, Lars Möllgård, Bertil Uggla, Anders Wahlin, Lovisa Wennström, Martin Höglund
Journal: Blood (2015)
Durable Responses to Lenalidomide (Revlimid®) in Patients with AL Amyloidosis: Follow Up of a Phase II Trial.
Authors: David C. Seldin, Michael Rosenzweig, Kathleen T. Finn, Salli Fennessey, Anthony Shelton, Jerome B. Zeldis, Martha Skinner, Vaishali Sanchorawala
Journal: Blood (2007)
In postmenopausal women, oral but not transdermal estrogen was associated with increased risk for stroke
Authors: Susan M. Ott
Journal: Annals of Internal Medicine (2016)

Source Citation Canonico M, Carcaillon L, Plu-Bureau G, et al. Postmenopausal hormone therapy and risk of stroke: impact of the route of estrogen administration and type of progestogen. Stroke. 2016;47:1734-41. 27256671
The Activation of Wnt5a-Mediated Non Canonical Wnt Signaling in Human Bone Marrow Osteoprogenitor Cells Increases Osteoblastogenesis and Counterbalances the Inhibitory Effect of Myeloma Cells on Ror2/FZD5 Expression,
Authors: Marina Bolzoni, Paola Storti, Daniela Guasco, Mirca Lazzaretti, Eugenia Martella, Cristina Mancini, Luca Agnelli, Sabrina Bonomini, Antonino Neri, Gaetano Donofrio, Nicola Giuliani
Journal: Blood (2011)
GW26-e4492 Inhibition of VDAC1 Prevents Ca2+-Mediated Oxidative Stress and Apoptosis Induced by 5-Aminolevulinic Acid Mediated Sonodynamic Therapy in THP-1 Macrophages
Authors: Weiwei Gao, Haibo Chen, Ye Tian
Journal: Journal of the American College of Cardiology (2015)
Effects of Liraglutide on Heart Rate and Heart Rate Variability: A Randomized, Double-Blind, Placebo-Controlled Crossover Study
Authors: Preman Kumarathurai, Christian Anholm, Bjørn S. Larsen, Rasmus Huan Olsen, Sten Madsbad, Ole Kristiansen, Olav W. Nielsen, Steen B. Haugaard, Ahmad Sajadieh
Journal: Diabetes Care (2016)

OBJECTIVE Reduced heart rate variability (HRV) and increased heart rate (HR) have been associated with cardiovascular mortality. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) increase HR, and studies have suggested that they may reduce HRV. We examined the effect of the GLP-1 RA liraglutide on HRV and diurnal variation of HR in overweight patients with newly diagnosed type 2 diabetes (T2D) and stable coronary artery disease (CAD). RESEARCH DESIGN AND METHODS Liraglutide or placebo was administrated to a backbone therapy of metformin in this double-blind, placebo-controlled 12 + 12–week crossover study. SD of beat-to-beat (NN) intervals (SDNN) was assessed by 24-h Holter monitoring as a measure of HRV. Diurnal HR variation and sympathovagal balance analyzed by root mean square of successive differences (RMSSD) in NN intervals and high-frequency (HF) and low-frequency (LF) power were assessed. RESULTS Compared with placebo, liraglutide decreased SDNN in 27 subjects (−33.9 ms; P &amp;lt; 0.001, paired analysis); decreased RMSSD (−0.3 log-ms; P = 0.025); and increased the mean HR (8.1 beats/min; P = 0.003), daytime HR (5.7; P = 0.083), and nighttime HR (6.3; P = 0.026). In a multivariable regression analysis, the decrease in SDNN remained significant after adjustment for metabolic and HR changes. Liraglutide reduced HF power (−0.7 log-ms2; P = 0.026) without any change in LF/HF ratio. CONCLUSIONS In overweight patients with CAD and newly diagnosed T2D, liraglutide increased HR and reduced HRV despite significant weight loss and improvement in metabolic parameters. The increase in nightly HR in conjunction with a decrease in parameters of parasympathetic activity suggests that liraglutide may affect sympathovagal balance.
Melanoma cell expression of macrophage markers in AJCC stage I/II melanoma.
Authors: T. O. Jensen, H. Schmidt, T. Steiniche, M. Hoyer, H. J. Moller
Journal: Journal of Clinical Oncology (2010)

e19034 Background: Tumor cells have the ability to fuse with host cells and it is hypothesised that a fusion between host macrophages and tumor cells causes hybrids with increased metastatic potential. CD163 and CD68 (PG-M1) are known as specific monocyte/macrophage markers. Aim: To study melanoma cell expression of macrophage markers CD163 and CD68 and their prognostic importance in patients with stage I/II disease. Methods: Formalin-fixated, paraffin-embedded primary melanomas from 190 stage I/II melanoma patients treated at the Plastic Surgery Department, Aarhus University Hospital in 1997 to 2002 were used. The melanoma cell expression of CD163 and CD68 was studied by immunohistochemistry (anti-CD163 [EDHu-1] and anti-CD68 [PG-M1]). The expression was evaluated as present or absent. Study endpoints were: Relapse-free survival and melanoma-specific survival. Results: Thirty-five and ten percent of the melanomas expressed CD163 and CD68, respectively. After a median follow-up period of 107 months (range, 1 to 137 months), 42 relapses (22%) and 32 melanoma-specific deaths (17%) were observed. CD163 and CD68 expression were analyzed separately together with ulceration and thickness in a Cox proportional hazard model. Melanoma cell expression of CD163 was an independent prognostic factor of relapse-free survival (HR = 3.1, 95%CI 1.5-6.1; p = 0.002) and melanoma-specific survival (HR = 3.7, 95%CI 1.7-8.0; p = 0.001), together with thickness. Melanoma cell expression of CD68 was only independently associated to poor relapse-free survival. Conclusions: Melanoma cell expression of macrophage markers is independently associated to poor survival. No significant financial relationships to disclose.
Purified Peripheral Autologous Stem Cell Transplant Versus Conventional Chemotherapy for Childhood Low Risk Relapsed Acute Lymphoblastic Leukemia.
Authors: Adriana Balduzzi, Maria Grazia Valsecchi, Stefania Galimberti, Sonia Bonanomi, Giuseppe Gaipa, Maria Dassi, Paolo Perseghin, Cornelia Eckert, Simona Songia, Monica Manenti, Andrea Biondi, Cornelio Uderzo, Guenter Henze, Arend von Stackelberg
Journal: Blood (2006)
Decreased Levels of Total or HDL Cholesterol in Primary Myelofibrosis Are Associated with Shortened Survival: DIPSS-Plus Independent Prognostic Value.
Authors: Nanna Sulai, Biruk Mengistu, Naseema Gangat, Curtis A. Hanson, Rhett P Ketterling, Animesh Pardanani, Ayalew Tefferi
Journal: Blood (2012)
Abstract A17: An integrin agonist suppresses breast cancer by reducing CD11b+ leukocytes, promoting anti-tumor immunity
Authors: Samia Q. Khan, Mohd H. Faridi, Brian Ruffell, Ana M. S. Lopez, Shehryar Jehangir, Antonio J. Barbosa, Marta Torroella-Kouri, Lisa M. Coussens, Judith Varner, Vineet Gupta
Journal: Cancer Research (2016)

Abstract Breast cancer remains the second highest cancer-related cause of death in women today. Neoadjuvant therapies reduce tumor size in patients but long-term survival remains poor. Tumor microenvironment shows a significant infiltration of CD11b+ tumor associated macrophages (TAMs) that promote tumor growth and metastases, while suppressing T-cell mediated anti-tumor immunity, suggesting that reducing infiltration of CD11b+ TAMs could have a therapeutic benefit. We recently developed a novel small molecule that targets CD11b+ cells and reduces their migration and tissue recruitment. Unlike previously described strategies, our methodology involves allosteric activation of CD11b, which induces transient increase in adhesion of CD11b+ cells to the vascular endothelium, thereby reducing the ability of the myeloid cells to transmigrate out of circulation and suppressing their recruitment into tumor and inflamed tissues. However, it is currently not known as to whether small molecule mediated CD11b activation can reduce TAM infiltration in tumors and whether that will have a therapeutic benefit. Here, we present results from studies with our lead compound leukadherin1 (LA1) in murine models of breast cancer. Our studies show that treatment of established syngeneic Cl66 orthotopic breast tumors in Balb/c mice with LA1 significantly reduces tumor growth and increases survival. LA1 treatment significantly reduced infiltration of CD11b+ cells into the tumor stroma, without affecting the levels of cells in circulation. LA1 treatment also significantly reduced expression of molecules that promote angiogenesis and tumor growth including MMP9, S100A8 and ARG1 that coincided with decreased CD31 and α-SMA, suggesting tumor vasculature disruption. Immune cell profiling revealed that LA1 treatment further promotes anti-tumor immunity by increasing the influx of cytotoxic CD8+ T cells into tumors. These data provide a rationale for using allosteric CD11b agonists to target TAM recruitment as a novel therapeutic approach for breast cancer. Citation Format: Samia Q. Khan, Mohd H. Faridi, Brian Ruffell, Ana M. S. Lopez, Shehryar Jehangir, Antonio J. Barbosa, Marta Torroella-Kouri, Lisa M. Coussens, Judith Varner, Vineet Gupta. An integrin agonist suppresses breast cancer by reducing CD11b+ leukocytes, promoting anti-tumor immunity. [abstract]. In: Proceedings of the AACR Special Conference: Function of Tumor Microenvironment in Cancer Progression; 2016 Jan 7–10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2016;76(15 Suppl):Abstract nr A17.
Preliminary results of a randomized phase II study of paclitaxel and bevacizumab ± gemcitabine as first-line treatment for metastatic breast cancer
Authors: K. L. Hoelzer, A. Brufsky, J. Hainsworth, J. T. Beck, R. Whorf, M. Keaton, J. Kroener, E. Krill-Jackson, S. Hu, J. Bromund
Journal: Journal of Clinical Oncology (2009)

1089 Background: The addition of bevacizumab (B) to paclitaxel (P) results in a significant improvement in PFS in pts with metastatic breast cancer (MBC) (Miller K, et al. New Engl J Med 2007). A randomized Phase II trial examining the efficacy and safety of adding gemcitabine (G) to the PB doublet has completed enrollment. Reported here are preliminary efficacy and safety results. Methods: This is a US, multicenter, randomized, superiority trial. Eligible pts have locally advanced or metastatic breast cancer, ECOG PS 0 or 1, and no prior cytotoxic therapy for metastatic disease. Prior adjuvant or neoadjuvant treatment with a taxane or endocrine therapy is allowed. Pts are randomized to receive P 90 mg/m 2 on Days 1, 8, and 15, followed by B 10 mg/kg on Days 1 and 15 of a 28-day cycle, or the same regimen plus G 1,500 mg/m 2 on Days 1 and 15. Primary endpoint is response rate according to RECIST criteria. Results: Between May 2006 and February 2008, 189 women were randomized to treatment. The table below summarizes currently available results. Grades 1–2 alopecia occurred in 28% of pts in the PB arm and in 38% of pts in the PB+G arm. One pt (2%) in the PB arm experienced a Grade 3 nosebleed. Grades 3 and 4 thrombotic events occurred respectively in 0% and 2% of pts in the PB arm, and in 3% and 2% of pts in the PB+G arm. Four pts (7%) in the PB arm and 3 pts (5%) in the PB+G arm discontinued due to treatment-related AEs. Three on-study deaths have occurred, none deemed related to study treatment. Conclusions: Study follow-up is ongoing. Full results will be available at the time of the meeting. Therapy with PB ± G is feasible and does not appear to be associated with significant bleeding or thrombotic events. As expected, the addition of G to the PB doublet appears to increase the incidence of neutropenia in pts with MBC. [Table: see text] [Table: see text]
CD4+ Lymphocytes in Asymptomatic HTLV-1 Carriers Present Cell Cycle Arrest in G0/G1-Phase
Authors: Mari Cleia Martins Rodrigues Ferreira, Renata Kikuchi Foltran, Rodrigo Santucci, Luis Alberto de Padua Covas Lage, Debora Levy, Juliana Pereira
Journal: Blood (2014)
Polymorphism nt7778G/T In Mitochondrial ATP8 Gene Promotes Protective Effect On Reactive Oxygen Species Level In Murine Hematopoietic Cells During Aging
Authors: Christin Kretzschmar, Catrin Roolf, Katrin Timmer, Gudrun Knübel, Anett Sekora, Sarah Müller, Markus Tiedge, Simone Baltrusch, Rüdiger Köhling, Saleh Ibrahim, Mathias Freund, Christian Junghanss
Journal: Blood (2013)